Comparison of Clindamycin Phosphate Vaginal Cream With Triple Sulfonamide Vaginal Cream in the Treatment of Bacterial Vaginosis
Background: Triple sulfonamide vaginal cream has been used to treat bacterial vaginosis for many years. There are few studies in which triple sulfonamide cream has been compared with newer regimens. Goal: To compare the efficacy and safety of clindamycin phosphate vaginal cream with that of triple s...
Gespeichert in:
Veröffentlicht in: | Sexually transmitted diseases 2001-10, Vol.28 (10), p.569-575 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 575 |
---|---|
container_issue | 10 |
container_start_page | 569 |
container_title | Sexually transmitted diseases |
container_volume | 28 |
creator | McCORMACK, WILLIAM M. COVINO, JEAN M. THOMASON, JESSICA L. ESCHENBACH, DAVID A. MOU, SUSAN KAPERNICK, PETER MCGREGOR, JAMES REIN, MICHAEL F. HILLIER, SHARON L. |
description | Background: Triple sulfonamide vaginal cream has been used to treat bacterial vaginosis for many years. There are few studies in which triple sulfonamide cream has been compared with newer regimens. Goal: To compare the efficacy and safety of clindamycin phosphate vaginal cream with that of triple sulfonamide vaginal cream in the treatment of bacterial vaginosis. Study Design: In this double-blind, randomized multicenter study, nonpregnant women 16 years of age or older with symptomatic bacterial vaginosis were assigned to receive either 2% clindamycin phosphate vaginal cream or triple sulfonamide vaginal cream for 7 days. Follow-up visits were conducted 5 to 10 days and 25 to 39 days after completion of treatment. Results: Clinical cure or improvement at 25 to 39 days was noted in 55 (69.6%) of 79 assessable participants who received clindamycin vaginal cream and in 33 (41.8%) of 79 women who received triple sulfonamide vaginal cream (P < 0.0001). Most of the difference between the treatment groups was noted in women with a history of bacterial vaginosis. Among women without a history of bacterial vaginosis, clindamycin and triple sulfonamide creams had similar efficacy. Evaluation of Gramstained vaginal smears correlated with clinical outcome. Most patients in both treatment groups reported an improvement in symptoms. No significant difference was observed between the treatment groups in the incidence of adverse events. Conclusion: Clindamycin 2% vaginal cream is more effective than triple sulfonamide vaginal cream in the treatment of bacterial vaginosis. |
doi_str_mv | 10.1097/00007435-200110000-00003 |
format | Article |
fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_journals_222373212</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>44965412</jstor_id><sourcerecordid>44965412</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-9aec09ba5c8d44679d073a2f5139c0cc64c6a78b7d4fd47e63a0a7e2eaee743b3</originalsourceid><addsrcrecordid>eNpdkE1r3DAQhkVoabZpf0KKKPToVp-WfWxMkxYCCSRNjmZWHne12JYjaQ859a9Xzm4TiA4SM3rmZXgIoZx95aw231g-RkldCMY4X6piueQRWXEtTaG04G_IinFVFdpwc0zex7hlS834O3LMeVnVRusV-dv4cYbgop-o72kzuKmD8dG6iV5vfJw3kJDewR83wUCbgDDSe5c29Da4eUB6sxt6P8HoutdUDkgbzBxCGnFKS_oZ2ITBZeaJ9dHFD-RtD0PEj4f3hPw-_3Hb_Cwury5-Nd8vC6sUS0UNaFm9Bm2rTqnS1B0zEkSvuawts7ZUtgRTrU2n-k4ZLCUwMCgQELOotTwhn_e5c_APO4yp3fpdyOvGVgghjRRcZKjaQzb4GAP27RzcCOGx5axdxLf_xbfP4p9aMo9-OuTv1iN2L4MH0xn4cgAgWhj6AJN18YWTsjKqVJk73XPbmHx4_leqLrXKO_4DjA6VyA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222373212</pqid></control><display><type>article</type><title>Comparison of Clindamycin Phosphate Vaginal Cream With Triple Sulfonamide Vaginal Cream in the Treatment of Bacterial Vaginosis</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Jstor Complete Legacy</source><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>McCORMACK, WILLIAM M. ; COVINO, JEAN M. ; THOMASON, JESSICA L. ; ESCHENBACH, DAVID A. ; MOU, SUSAN ; KAPERNICK, PETER ; MCGREGOR, JAMES ; REIN, MICHAEL F. ; HILLIER, SHARON L.</creator><creatorcontrib>McCORMACK, WILLIAM M. ; COVINO, JEAN M. ; THOMASON, JESSICA L. ; ESCHENBACH, DAVID A. ; MOU, SUSAN ; KAPERNICK, PETER ; MCGREGOR, JAMES ; REIN, MICHAEL F. ; HILLIER, SHARON L.</creatorcontrib><description>Background: Triple sulfonamide vaginal cream has been used to treat bacterial vaginosis for many years. There are few studies in which triple sulfonamide cream has been compared with newer regimens. Goal: To compare the efficacy and safety of clindamycin phosphate vaginal cream with that of triple sulfonamide vaginal cream in the treatment of bacterial vaginosis. Study Design: In this double-blind, randomized multicenter study, nonpregnant women 16 years of age or older with symptomatic bacterial vaginosis were assigned to receive either 2% clindamycin phosphate vaginal cream or triple sulfonamide vaginal cream for 7 days. Follow-up visits were conducted 5 to 10 days and 25 to 39 days after completion of treatment. Results: Clinical cure or improvement at 25 to 39 days was noted in 55 (69.6%) of 79 assessable participants who received clindamycin vaginal cream and in 33 (41.8%) of 79 women who received triple sulfonamide vaginal cream (P < 0.0001). Most of the difference between the treatment groups was noted in women with a history of bacterial vaginosis. Among women without a history of bacterial vaginosis, clindamycin and triple sulfonamide creams had similar efficacy. Evaluation of Gramstained vaginal smears correlated with clinical outcome. Most patients in both treatment groups reported an improvement in symptoms. No significant difference was observed between the treatment groups in the incidence of adverse events. Conclusion: Clindamycin 2% vaginal cream is more effective than triple sulfonamide vaginal cream in the treatment of bacterial vaginosis.</description><identifier>ISSN: 0148-5717</identifier><identifier>EISSN: 1537-4521</identifier><identifier>DOI: 10.1097/00007435-200110000-00003</identifier><identifier>PMID: 11689755</identifier><identifier>CODEN: STRDDM</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Administration, Intravaginal ; Adolescent ; Adult ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - therapeutic use ; Anti-Infective Agents - administration & dosage ; Anti-Infective Agents - adverse effects ; Anti-Infective Agents - therapeutic use ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacteria ; Biological and medical sciences ; Clindamycin - administration & dosage ; Clindamycin - adverse effects ; Clindamycin - analogs & derivatives ; Clindamycin - therapeutic use ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Infections ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Prescription drugs ; Recurrence ; Sexually transmitted diseases ; STD ; Sulfonamides - administration & dosage ; Sulfonamides - adverse effects ; Sulfonamides - therapeutic use ; Treatment Outcome ; Vaginal Creams, Foams, and Jellies ; Vaginosis, Bacterial - drug therapy ; Vaginosis, Bacterial - microbiology</subject><ispartof>Sexually transmitted diseases, 2001-10, Vol.28 (10), p.569-575</ispartof><rights>Copyright © 2001 American Sexually Transmitted Diseases Association</rights><rights>2002 INIST-CNRS</rights><rights>Copyright Lippincott Williams & Wilkins Oct 2001</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-9aec09ba5c8d44679d073a2f5139c0cc64c6a78b7d4fd47e63a0a7e2eaee743b3</citedby><cites>FETCH-LOGICAL-c440t-9aec09ba5c8d44679d073a2f5139c0cc64c6a78b7d4fd47e63a0a7e2eaee743b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/44965412$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/44965412$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,27924,27925,30999,58017,58250</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13387464$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11689755$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McCORMACK, WILLIAM M.</creatorcontrib><creatorcontrib>COVINO, JEAN M.</creatorcontrib><creatorcontrib>THOMASON, JESSICA L.</creatorcontrib><creatorcontrib>ESCHENBACH, DAVID A.</creatorcontrib><creatorcontrib>MOU, SUSAN</creatorcontrib><creatorcontrib>KAPERNICK, PETER</creatorcontrib><creatorcontrib>MCGREGOR, JAMES</creatorcontrib><creatorcontrib>REIN, MICHAEL F.</creatorcontrib><creatorcontrib>HILLIER, SHARON L.</creatorcontrib><title>Comparison of Clindamycin Phosphate Vaginal Cream With Triple Sulfonamide Vaginal Cream in the Treatment of Bacterial Vaginosis</title><title>Sexually transmitted diseases</title><addtitle>Sex Transm Dis</addtitle><description>Background: Triple sulfonamide vaginal cream has been used to treat bacterial vaginosis for many years. There are few studies in which triple sulfonamide cream has been compared with newer regimens. Goal: To compare the efficacy and safety of clindamycin phosphate vaginal cream with that of triple sulfonamide vaginal cream in the treatment of bacterial vaginosis. Study Design: In this double-blind, randomized multicenter study, nonpregnant women 16 years of age or older with symptomatic bacterial vaginosis were assigned to receive either 2% clindamycin phosphate vaginal cream or triple sulfonamide vaginal cream for 7 days. Follow-up visits were conducted 5 to 10 days and 25 to 39 days after completion of treatment. Results: Clinical cure or improvement at 25 to 39 days was noted in 55 (69.6%) of 79 assessable participants who received clindamycin vaginal cream and in 33 (41.8%) of 79 women who received triple sulfonamide vaginal cream (P < 0.0001). Most of the difference between the treatment groups was noted in women with a history of bacterial vaginosis. Among women without a history of bacterial vaginosis, clindamycin and triple sulfonamide creams had similar efficacy. Evaluation of Gramstained vaginal smears correlated with clinical outcome. Most patients in both treatment groups reported an improvement in symptoms. No significant difference was observed between the treatment groups in the incidence of adverse events. Conclusion: Clindamycin 2% vaginal cream is more effective than triple sulfonamide vaginal cream in the treatment of bacterial vaginosis.</description><subject>Administration, Intravaginal</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-Infective Agents - administration & dosage</subject><subject>Anti-Infective Agents - adverse effects</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacteria</subject><subject>Biological and medical sciences</subject><subject>Clindamycin - administration & dosage</subject><subject>Clindamycin - adverse effects</subject><subject>Clindamycin - analogs & derivatives</subject><subject>Clindamycin - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Infections</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prescription drugs</subject><subject>Recurrence</subject><subject>Sexually transmitted diseases</subject><subject>STD</subject><subject>Sulfonamides - administration & dosage</subject><subject>Sulfonamides - adverse effects</subject><subject>Sulfonamides - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Vaginal Creams, Foams, and Jellies</subject><subject>Vaginosis, Bacterial - drug therapy</subject><subject>Vaginosis, Bacterial - microbiology</subject><issn>0148-5717</issn><issn>1537-4521</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNpdkE1r3DAQhkVoabZpf0KKKPToVp-WfWxMkxYCCSRNjmZWHne12JYjaQ859a9Xzm4TiA4SM3rmZXgIoZx95aw231g-RkldCMY4X6piueQRWXEtTaG04G_IinFVFdpwc0zex7hlS834O3LMeVnVRusV-dv4cYbgop-o72kzuKmD8dG6iV5vfJw3kJDewR83wUCbgDDSe5c29Da4eUB6sxt6P8HoutdUDkgbzBxCGnFKS_oZ2ITBZeaJ9dHFD-RtD0PEj4f3hPw-_3Hb_Cwury5-Nd8vC6sUS0UNaFm9Bm2rTqnS1B0zEkSvuawts7ZUtgRTrU2n-k4ZLCUwMCgQELOotTwhn_e5c_APO4yp3fpdyOvGVgghjRRcZKjaQzb4GAP27RzcCOGx5axdxLf_xbfP4p9aMo9-OuTv1iN2L4MH0xn4cgAgWhj6AJN18YWTsjKqVJk73XPbmHx4_leqLrXKO_4DjA6VyA</recordid><startdate>20011001</startdate><enddate>20011001</enddate><creator>McCORMACK, WILLIAM M.</creator><creator>COVINO, JEAN M.</creator><creator>THOMASON, JESSICA L.</creator><creator>ESCHENBACH, DAVID A.</creator><creator>MOU, SUSAN</creator><creator>KAPERNICK, PETER</creator><creator>MCGREGOR, JAMES</creator><creator>REIN, MICHAEL F.</creator><creator>HILLIER, SHARON L.</creator><general>Lippincott Williams & Wilkins</general><general>Lippincott</general><general>Lippincott Williams & Wilkins Ovid Technologies</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7QL</scope><scope>7T2</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope></search><sort><creationdate>20011001</creationdate><title>Comparison of Clindamycin Phosphate Vaginal Cream With Triple Sulfonamide Vaginal Cream in the Treatment of Bacterial Vaginosis</title><author>McCORMACK, WILLIAM M. ; COVINO, JEAN M. ; THOMASON, JESSICA L. ; ESCHENBACH, DAVID A. ; MOU, SUSAN ; KAPERNICK, PETER ; MCGREGOR, JAMES ; REIN, MICHAEL F. ; HILLIER, SHARON L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-9aec09ba5c8d44679d073a2f5139c0cc64c6a78b7d4fd47e63a0a7e2eaee743b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Administration, Intravaginal</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-Infective Agents - administration & dosage</topic><topic>Anti-Infective Agents - adverse effects</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacteria</topic><topic>Biological and medical sciences</topic><topic>Clindamycin - administration & dosage</topic><topic>Clindamycin - adverse effects</topic><topic>Clindamycin - analogs & derivatives</topic><topic>Clindamycin - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Infections</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prescription drugs</topic><topic>Recurrence</topic><topic>Sexually transmitted diseases</topic><topic>STD</topic><topic>Sulfonamides - administration & dosage</topic><topic>Sulfonamides - adverse effects</topic><topic>Sulfonamides - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Vaginal Creams, Foams, and Jellies</topic><topic>Vaginosis, Bacterial - drug therapy</topic><topic>Vaginosis, Bacterial - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McCORMACK, WILLIAM M.</creatorcontrib><creatorcontrib>COVINO, JEAN M.</creatorcontrib><creatorcontrib>THOMASON, JESSICA L.</creatorcontrib><creatorcontrib>ESCHENBACH, DAVID A.</creatorcontrib><creatorcontrib>MOU, SUSAN</creatorcontrib><creatorcontrib>KAPERNICK, PETER</creatorcontrib><creatorcontrib>MCGREGOR, JAMES</creatorcontrib><creatorcontrib>REIN, MICHAEL F.</creatorcontrib><creatorcontrib>HILLIER, SHARON L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Sexually transmitted diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McCORMACK, WILLIAM M.</au><au>COVINO, JEAN M.</au><au>THOMASON, JESSICA L.</au><au>ESCHENBACH, DAVID A.</au><au>MOU, SUSAN</au><au>KAPERNICK, PETER</au><au>MCGREGOR, JAMES</au><au>REIN, MICHAEL F.</au><au>HILLIER, SHARON L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Clindamycin Phosphate Vaginal Cream With Triple Sulfonamide Vaginal Cream in the Treatment of Bacterial Vaginosis</atitle><jtitle>Sexually transmitted diseases</jtitle><addtitle>Sex Transm Dis</addtitle><date>2001-10-01</date><risdate>2001</risdate><volume>28</volume><issue>10</issue><spage>569</spage><epage>575</epage><pages>569-575</pages><issn>0148-5717</issn><eissn>1537-4521</eissn><coden>STRDDM</coden><abstract>Background: Triple sulfonamide vaginal cream has been used to treat bacterial vaginosis for many years. There are few studies in which triple sulfonamide cream has been compared with newer regimens. Goal: To compare the efficacy and safety of clindamycin phosphate vaginal cream with that of triple sulfonamide vaginal cream in the treatment of bacterial vaginosis. Study Design: In this double-blind, randomized multicenter study, nonpregnant women 16 years of age or older with symptomatic bacterial vaginosis were assigned to receive either 2% clindamycin phosphate vaginal cream or triple sulfonamide vaginal cream for 7 days. Follow-up visits were conducted 5 to 10 days and 25 to 39 days after completion of treatment. Results: Clinical cure or improvement at 25 to 39 days was noted in 55 (69.6%) of 79 assessable participants who received clindamycin vaginal cream and in 33 (41.8%) of 79 women who received triple sulfonamide vaginal cream (P < 0.0001). Most of the difference between the treatment groups was noted in women with a history of bacterial vaginosis. Among women without a history of bacterial vaginosis, clindamycin and triple sulfonamide creams had similar efficacy. Evaluation of Gramstained vaginal smears correlated with clinical outcome. Most patients in both treatment groups reported an improvement in symptoms. No significant difference was observed between the treatment groups in the incidence of adverse events. Conclusion: Clindamycin 2% vaginal cream is more effective than triple sulfonamide vaginal cream in the treatment of bacterial vaginosis.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>11689755</pmid><doi>10.1097/00007435-200110000-00003</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0148-5717 |
ispartof | Sexually transmitted diseases, 2001-10, Vol.28 (10), p.569-575 |
issn | 0148-5717 1537-4521 |
language | eng |
recordid | cdi_proquest_journals_222373212 |
source | Applied Social Sciences Index & Abstracts (ASSIA); Jstor Complete Legacy; MEDLINE; Journals@Ovid Complete |
subjects | Administration, Intravaginal Adolescent Adult Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Anti-Infective Agents - administration & dosage Anti-Infective Agents - adverse effects Anti-Infective Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Bacteria Biological and medical sciences Clindamycin - administration & dosage Clindamycin - adverse effects Clindamycin - analogs & derivatives Clindamycin - therapeutic use Double-Blind Method Female Follow-Up Studies Humans Infections Medical sciences Middle Aged Pharmacology. Drug treatments Prescription drugs Recurrence Sexually transmitted diseases STD Sulfonamides - administration & dosage Sulfonamides - adverse effects Sulfonamides - therapeutic use Treatment Outcome Vaginal Creams, Foams, and Jellies Vaginosis, Bacterial - drug therapy Vaginosis, Bacterial - microbiology |
title | Comparison of Clindamycin Phosphate Vaginal Cream With Triple Sulfonamide Vaginal Cream in the Treatment of Bacterial Vaginosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A35%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Clindamycin%20Phosphate%20Vaginal%20Cream%20With%20Triple%20Sulfonamide%20Vaginal%20Cream%20in%20the%20Treatment%20of%20Bacterial%20Vaginosis&rft.jtitle=Sexually%20transmitted%20diseases&rft.au=McCORMACK,%20WILLIAM%20M.&rft.date=2001-10-01&rft.volume=28&rft.issue=10&rft.spage=569&rft.epage=575&rft.pages=569-575&rft.issn=0148-5717&rft.eissn=1537-4521&rft.coden=STRDDM&rft_id=info:doi/10.1097/00007435-200110000-00003&rft_dat=%3Cjstor_proqu%3E44965412%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222373212&rft_id=info:pmid/11689755&rft_jstor_id=44965412&rfr_iscdi=true |